
## Eugenia V Broude

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6788625/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	lf not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resistance Updates, 2001, 4, 303-313.	14.4	625
2	Role of p53 and p21waf1/cip1 in senescence-like terminal proliferation arrest induced in human tumor cells by chemotherapeutic drugs. Oncogene, 1999, 18, 4808-4818.	5.9	352
3	Structural insight into substrate and inhibitor discrimination by human P-glycoprotein. Science, 2019, 363, 753-756.	12.6	330
4	Molecular determinants of terminal growth arrest induced in tumor cells by a chemotherapeutic agent. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 389-394.	7.1	272
5	p21Waf1/Cip1/Sdi1-induced growth arrest is associated with depletion of mitosis-control proteins and leads to abnormal mitosis and endoreduplication in recovering cells. Oncogene, 2000, 19, 2165-2170.	5.9	171
6	Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1973-E1982.	7.1	153
7	Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13799-13804.	7.1	146
8	Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget, 2017, 8, 12558-12575.	1.8	92
9	CDK8/19 Mediator kinases potentiate induction of transcription by NFκB. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10208-10213.	7.1	89
10	Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer. Current Cancer Drug Targets, 2015, 15, 739-749.	1.6	67
11	CDK8 Selectively Promotes the Growth of Colon Cancer Metastases in the Liver by Regulating Gene Expression of TIMP3 and Matrix Metalloproteinases. Cancer Research, 2018, 78, 6594-6606.	0.9	65
12	p21 (CDKN1A) is a Negative Regulator of p53 Stability. Cell Cycle, 2007, 6, 1467-1470.	2.6	53
13	Mediator kinase CDK8/CDK19 drives YAP1-dependent BMP4-induced EMT in cancer. Oncogene, 2018, 37, 4792-4808.	5.9	49
14	Tumor-specific silencing of COPZ2 gene encoding coatomer protein complex subunit Â2 renders tumor cells dependent on its paralogous gene COPZ1. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12449-12454.	7.1	40
15	Cellular Model of p21-Induced Senescence. Methods in Molecular Biology, 2017, 1534, 31-39.	0.9	39
16	Notch inhibition in Kaposi's sarcoma tumor cells leads to mitotic catastrophe through nuclear factor-κB signaling. Molecular Cancer Therapeutics, 2007, 6, 1983-1992.	4.1	36
17	Identification of novel cancer therapeutic targets using a designed and pooled shRNA library screen. Scientific Reports, 2017, 7, 43023.	3.3	33
18	Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition. Cells, 2019, 8, 1413.	4.1	33

Eugenia V Broude

#	Article	IF	CITATIONS
19	Inhibin Is a Novel Paracrine Factor for Tumor Angiogenesis and Metastasis. Cancer Research, 2018, 78, 2978-2989.	0.9	32
20	Effects of conditional depletion of topoisomerase II on cell cycle progression in mammalian cells. Cell Cycle, 2011, 10, 3505-3514.	2.6	31
21	Identifying Cancers Impacted by CDK8/19. Cells, 2019, 8, 821.	4.1	31
22	CDK7 Inhibition Is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition. Cells, 2020, 9, 638.	4.1	24
23	A Combination of Genetic Suppressor Elements Produces Resistance to Drugs Inhibiting DNA Replication. Somatic Cell and Molecular Genetics, 1999, 25, 9-26.	0.7	19
24	Pharmacological inhibition of DEAD-Box RNA Helicase 3 attenuates stress granule assembly. Biochemical Pharmacology, 2020, 182, 114280.	4.4	19
25	Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells. Oncotarget, 2015, 6, 13088-13104.	1.8	18
26	The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs. Cells, 2021, 10, 144.	4.1	16
27	Function-based gene identification using enzymatically generated normalized shRNA library and massive parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7377-7382.	7.1	15
28	Characterizing CDK8/19 Inhibitors through a NFκB-Dependent Cell-Based Assay. Cells, 2019, 8, 1208.	4.1	11
29	Inhibition of the Dead Box RNA Helicase 3 Prevents HIV-1 Tat and Cocaine-Induced Neurotoxicity by Targeting Microglia Activation. Journal of NeuroImmune Pharmacology, 2020, 15, 209-223.	4.1	11
30	Down-Regulation of Cyclin F Levels during Nerve Growth Factor-Induced Differentiation of PC12 Cells. Experimental Cell Research, 1996, 227, 203-207.	2.6	8
31	Role of transcription-regulating kinase CDK8 in colon cancer metastasis. Oncotarget, 2019, 10, 622-623.	1.8	6
32	Abstract LB-401: The chemosensitizing properties of iniparib in combination with DNA-damaging agents in the MDA-MB-468(â^²) triple-negative breast cancer (TNBC) cell line. , 2011, , .		5
33	Mitotic Catastrophe in Cancer Therapy. , 2008, , 307-320.		5
34	Abstract 4879: Targeting the seed and the soil of cancers with selective small-molecule inhibitors of CDK8/19: Chemopotentiating, chemopreventive, anti-invasive and anti-metastatic activities. Cancer Research, 2014, 74, 4879-4879.	0.9	3
35	THERAPY-INDUCED SENESCENCE RESPONSE AND DIFFERENTIAL GENE EXPRESSION IN PROSTATE CANCER CELLS WITH VARIABLE METASTATIC POTENTIAL. Journal of Urology, 2008, 179, 191-192.	0.4	1
36	Abstract 1820: CDK3: A novel tumor-selective drug target involved in AP1 activation and transcriptional damage response. Cancer Research, 2012, 72, 1820-1820.	0.9	1

Eugenia V Broude

#	Article	IF	CITATIONS
37	Abstract PR08: Targeting tumor microenvironment with selective small-molecule inhibitors of CDK8/19. , 2015, , .		1
38	Abstract 4896: Role of CDK8 in colon cancer hepatic metastasis. , 2017, , .		1
39	EXPRESSION OF SENESCENCE-ASSOCIATED GROWTH REGULATORY PROTEINS IN HUMAN PROSTATE CANCER. Journal of Urology, 2009, 181, 514-514.	0.4	0
40	Abstract LB132: CDK8/19 inhibition overcomes in vitro and in vivo resistance to lapatinib in HER2+ breast cancer via STAT1 and STAT3. , 2021, , .		0
41	Abstract 2101: Role of CDK8 in estrogen receptor signaling in breast cancers. , 2014, , .		0
42	Abstract 4883: CDK8: A new druggable mediator of NFÎ $^{\circ}$ B activity. , 2014, , .		0
43	Abstract P4-15-13: CDK8 inhibition potentiates anti-ER and anti-HER2 therapies in breast cancer. , 2015, , .		0
44	Abstract 5459: Overcoming resistance to HER2-targeting drugs using CDK8 inhibitors. , 2015, , .		0
45	Abstract 1512: Functional characterization of novel transcription-regulating cancer drug targets, CDK8 and CDK19, using CRISPR/Cas9 knockout and a highly selective CDK8/19 kinase inhibitor. , 2017, , .		0
46	Abstract 89: Role of CDK8 and CDK19 in STAT1 phosphorylation at serine 727. , 2020, , .		0